Epigenome editing — gene control without cutting
Chroma Medicine develops epigenome editing therapies that can silence or activate genes without making any cuts to DNA. Their technology modifies the epigenetic marks on DNA, offering a potentially safer alternative to traditional gene editing.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| CHR-400 | Chronic Hepatitis B | Preclinical | Epigenome Editing |
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.